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AbstrACt
Objectives Healthcare budgets are limited, and 
therefore, research funds should be wisely allocated 
to ensure high-quality, useful and cost-effective 
research. We aimed to critically review the criteria 
considered by major Australian organisations in 
prioritising and selecting health research projects for 
funding.
Methods We reviewed all grant schemes listed 
on the Australian Competitive Grants Register that 
were health-related, active in 2017 and with publicly 
available selection criteria on the funders’ websites. 
Data extracted included scheme name, funding 
organisation, selection criteria and the relative weight 
assigned to each criterion. Selection criteria were 
grouped into five representative domains: relevance, 
appropriateness, significance, feasibility (including 
team quality) and cost-effectiveness (ie, value for 
money).
results Thirty-six schemes were included from 158 
identified. One-half of the schemes were under the 
National Health and Medical Research Council. The 
most commonly used criteria were research team 
quality and capability (94%), research plan clarity 
(94%), scientific quality (92%) and research impact 
(92%). Criteria considered less commonly were 
existing knowledge (22%), fostering collaboration 
(22%), research environment (19%), value for 
money (14%), disease burden (8%) and ethical/
moral considerations (3%). In terms of representative 
domains, relevance was considered in 72% of the 
schemes, appropriateness in 92%, significance in 
94%, feasibility in 100% and cost-effectiveness in 
17%. The relative weights for the selection criteria 
varied across schemes with 5%–30% for relevance, 
20%–60% for each appropriateness and significance, 
20%–75% for feasibility and 15%–33% for cost-
effectiveness.
Conclusions In selecting research projects for 
funding, Australian research organisations focus 
largely on research appropriateness, significance 
and feasibility; however, value for money is most 
often overlooked. Research funding decisions should 
include an assessment of value for money in order to 
maximise return on research investment.
IntrOduCtIOn 
Research is vital to generate evidence to 
guide medical decision making and improve 
health. Therefore, the Australian Govern-
ment and various research organisations 
allocate considerable resources to fund 
clinical trials and other health research. 
The total expenditure on health research 
in Australia was around $A5.4 billion in 
2014.1 Recently, the Australian Government 
has announced the establishment of the 
$A20 billion Medical Research Future Fund, 
which aims to improve health, contribute to a 
sustainable health system and provide signif-
icant economic benefits.2 There has been an 
emerging interest in Australia and interna-
tionally to maximise value and reduce waste 
in healthcare research.3–5 Although research 
value should be ensured throughout the 
continuum (ie, from research question devel-
opment to implementation of the findings), 
directing research funds to the right research 
strengths and limitations of this study
 ► The first critical review of research project selection 
criteria from a funder perspective in Australia.
 ► A comprehensive review of available funding 
schemes, selection criteria and scoring weights to 
prioritise research proposals.
 ► The recommendations provided will help research 
organisations streamline funding to worthy projects 
to maximise return on research investment.
 ► The review takes an Australian perspective, but the 
findings and recommendations maybe applicable to 
other jurisdictions.
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projects in the first place is key to optimise health and 
economic benefits from healthcare research. This is typi-
cally achieved at two levels: 1) selecting strategic research 
areas or topics (eg, indigenous health or cancer) to 
guide overall research activity and commissioning and 
2) selecting specific research projects for funding from 
proposals put forward by researchers.6 7 
Most research projects in Australia are investigator-ini-
tiated and researchers must seek financial support for 
their proposals through research funding organisations 
(eg, the National Health and Medical Research Council 
(NHMRC)). However, the overall funds available for 
research are limited compared with the number of 
submissions and decisions have to be made about the 
best way to distribute research funds. Thus, funding 
organisations need to have a transparent and system-
atic way to evaluate and prioritise research projects for 
funding.5 8 9 This is often done based on the assessments 
of the merits of the submitted proposals according to the 
judgements of experts sitting on funding panels.8 10 In 
this process, submitted proposals are assessed and scored 
against predefined criteria with each criterion, or group 
of criteria, being assigned a weight reflecting its relative 
importance. Such practice corroborates with the recom-
mendations of many international initiatives for setting 
research priorities where the use of explicit and compre-
hensive criteria is encouraged to ensure that important 
considerations are not overlooked during the selection 
process.9 11–14 In general, these criteria may include 
burden of the disease, equity, scientific rigour, research 
team capabilities, innovation and impact of research 
results. The choice of criteria and the scoring system may 
differ, depending on the needs of stakeholders involved 
in this exercise.9 11–14 Literature examples on prioritising 
research topics using explicit criteria are abundant9 11–14; 
however, there is a dearth of articles that provide a clear 
critical insight on the criteria used to select research proj-
ects from research proposals competing for funding.15
While health research funding decisions in Australia 
rely heavily on the ability of research proposals to meet 
selection criteria, it is unknown what criteria are more 
commonly used by research funders, how these criteria 
and their weights vary across funding organisations, 
and whether these criteria are comprehensive enough 
to capture all important considerations to ensure high 
quality and value for money research. This knowledge 
is important to assess the current approach of selecting 
and funding research projects, and to guide future 
efforts to optimise health research funding mechanisms 
in the country. Therefore, the aim of this paper was to 
critically review the criteria considered by major Austra-
lian research organisations in their selection of health 
research projects for funding.
MethOds
Patient and public involvement
Patients and public were not involved.
We reviewed all research funding schemes listed on 
the Australian Competitive Grants Register (ACGR), 
which provides a comprehensive list of funding schemes 
that have been approved by the Australian Government 
as being competitive research grants.16 The identi-
fied schemes were included if they were health related, 
active in 2017 and had clear selection criteria which 
were publicly available on the funders’ websites. Health 
research refers to research with human health or medical 
purpose, including research on the aetiology, diagnosis or 
management of disease, mental condition or behaviour in 
human. To focus on schemes for funding research proj-
ects and programmes, research schemes dedicated solely 
to training, capacity building, equipment or infrastruc-
ture were excluded. These include fellowships, awards 
and scholarships as well as research and training centres.
Data extracted included scheme name, year first imple-
mented, funding organisation, selection criteria and 
the relative weight assigned to each criterion. Selection 
criteria were grouped into five representative domains: 
relevance (ie, why should we do it? including the burden 
of disease and level of existing knowledge), appropriate-
ness (ie, should we do it? including scientific rigour and 
suitability to answer the research question), significance of 
research outcomes (ie, what will we get out of it? including 
impact and innovation), feasibility (ie, can we do it? 
including team quality and research environment) and 
cost-effectiveness (ie, is the proposed research potentially 
good value for money?).9 12 The domains were selected 
based on the lists of criteria and categories suggested in 
comprehensive tools for research prioritisation including 
the Essential National Health Research Approach (rele-
vance, appropriateness, feasibility and significance),12 
Child Health and Nutrition Research Initiative (answer-
ability, effectiveness, deliverability and impact)11 and the 
Checklist for Health Research Priority Setting (benefits, 
feasibility and cost-effectiveness).9 Disagreements related 
to assigning criteria to their representative domains were 
either resolved by discussion or the involvement of a 
third reviewer who was provided with the full assessment 
or selection criteria for consensus decision-making. A 
domain was counted under a given scheme if at least one 
criterion within that domain is reported in the selection 
criteria of that scheme. Table 1 provides a description of 
the representative domains.
results
Thirty-six schemes met our inclusion criteria from 158 
schemes listed on the 2017 ACGR. Figure 1 summarises 
the review process.
One-half of the schemes were under the NHMRC. Five 
schemes (14%) were specifically for research in cancer, 
four (11%) for dementia, four (11%) for mental health 
and three (8%) for diabetes. A summary of the selection 
criteria considered by each scheme is presented in table 2. 
Further details on the selection criteria and scoring 
weights are provided in online supplementary file.
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The most commonly used criteria were research team 
quality and capability (94%), research plan clarity (94%), 
scientific quality of the proposal (92%) and research 
impact (92%). Criteria considered less commonly were 
existing knowledge (22%), fostering collaboration 
(22%), research environment (19%), budget justifica-
tion (17%), value for money (14%), disease burden (8%) 
and ethical/moral considerations (3%). When selection 
criteria were grouped into relevant domains, all schemes 
considered feasibility criteria, 94% of the schemes consid-
ered significance, 92% considered appropriateness, 
72% considered relevance and only 17% considered 
cost-effectiveness. Only five schemes (14%) consid-
ered all five domains namely, NHMRC National Insti-
tute for Dementia Research Grants, NHMRC Boosting 
Dementia Research Grants, Cancer Australia Clinical 
Trials Programme, the Department of Foreign Affairs 
and Trade Tropical Disease Research, Health Promotion 
Intervention Research Grants. Figure 2 depicts the distri-
bution of selection criteria.
When reported, the relative weights for the selection 
criteria also varied across schemes with 20%–75% for 
Table 1 Description of domains and relevant criteria9 12
Domain Definition
Relevance The key question for this domain is “why should we do it?” The proposed research is pertinent to the 
health problems of interest. It takes into consideration burden of disease, equity, alignment with national/
organisational objectives and the level of existing knowledge in relation to the intervention.
Appropriateness The key question for this domain is “should we do it?” The proposed research is well suited to answer the 
decision problem (ie, answerability). It takes into consideration ethical, moral and legal acceptability, and 
scientific rigour.
Significance The key question for this domain is “what will we get out of it?” It represents the benefit of implementing/
translating the research results. It takes into consideration the impact on health, innovation and ability to 
foster capacity building and collaboration.
Feasibility The key question for this domain is “can we do it?” The focus is on the chances of research success. It 
considers team quality (track record) and capability, research environment and the research plan.
Cost-effectiveness The key question for this domain is ‘is the research cost-effective?’ This theme focuses on the value for 
money of the research proposal and budget justification. It considers the costs and expected benefits of 
conducting research.
Figure 1 Flow chart of the review.
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feasibility, 20%–60% for each appropriateness and signif-
icance, 15%–33% for value for money and 5%–30% for 
relevance criteria.
dIsCussIOn
Using a predefined set of selection criteria is a trans-
parent approach to select and prioritise high-quality 
research projects for funding. Typically, the relevance of 
research proposals is gauged with criteria that are mostly 
related to the project’s ability to advance knowledge7; 
however, these criteria should also reflect the mandate of 
the funding organisation and the purpose of the funding 
scheme.9 12 A broad range of criteria were reported in the 
included schemes with a clear focus on the quality of the 
research team, research plan, scientific rigour, impact 
and translation/implementation potential. The identi-
fied schemes, within the same organisation and across 
organisations, had variable selection criteria and scoring 
weights. When grouped into representative domains, 
funding organisations in Australia appear to focus on 
research relevance, appropriateness, significance and 
feasibility; however, cost-effectiveness of research proj-
ects was largely overlooked. The observed variation in 
criteria and scoring weights in our review may be justi-
fied by the different emphasis placed on certain aspects 
to achieve the outcomes sought under each scheme. For 
instance, collaborative and partnership schemes focused 
on partnership strengths, collaborative gains and team 
integration.
The only aspect that was considered by all schemes was 
research feasibility with a clear emphasis on the quality 
of the research team. Team quality and capability (often 
based on past performance) is vital to ensure that the 
funded research projects can be effectively conducted 
within the time and budget specified; nevertheless, over 
relying on this criterion may result in giving dispropor-
tionate share of funding to established teams at the 
expense of more novel and innovative projects. This bias 
can be reduced by introducing initiatives that fund inno-
vative research ideas with high impact potential such as 
the ‘Grand Challenges’ initiative and the NMRC ‘Ideas 
Grants’.5 6 Notably, there are important criteria that were 
not considered by most of the included schemes. Equity 
considerations were not explicitly mentioned as a selec-
tion criterion, and ethical/moral considerations were 
only considered in one scheme. This might be explained 
by the implicit assumptions that all submitted proposals 
will be approved by ethics committees and that equity is 
addressed by targeted research grants (eg, Research in 
Aboriginal and Torres Strait Islanders) or considered 
during final deliberations to select proposals for funding. 
However, without clarity about where the responsibility 
for ethical and equity considerations lies there is the 
potential for these criteria to be overlooked.
There has been a shift away from exclusive technical 
merit-review of proposals towards relevance of research 
funding as judged by multiple stakeholders.7 17 18 Research 
organisations, particularly if publicly funded, are increas-
ingly expected to make the best use of taxpayers’ money 
Figure 2 Overall research criteria and their representative domains.
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to increase value and reduce waste when research priori-
ties are set.19 20 For example, Chalmers et al recommended 
to engage potential users of research in research prioriti-
sation, justify additional research by systematic reviews to 
show what is already known and to periodically monitor 
and analyse impact of funded research.4 5 21 Around 40% 
of the schemes in our study considered stakeholders’ 
involvement (ie, consumers and/or clinicians); however, 
the level of stakeholders’ engagement and influence on 
funding decisions was unclear. Considering the needs 
and inputs of various stakeholders such as patients, care-
givers, clinicians and decision makers is essential to fund 
research that is useful to solve real-life problems. The 
experience of the Patient-Centred Outcomes Research 
Institute in the USA suggested that involving patients and 
stakeholders alongside scientists in reviewing research 
applications is influential in panel discussions and merit 
review outcomes.18 22 Despite its importance to avoid 
research duplication, only 22% of the identified schemes 
considered existing knowledge, but none of the schemes 
explicitly required a systematic review of literature to 
demonstrate knowledge gaps. Although conducting 
systematic reviews to identify knowledge gaps may not be 
required when responding to targeted research calls or 
when research is commissioned, since evidence review 
is often conducted by the commissioning organisations, 
showing what is already known should be required by 
researchers submitting investigator-initiated proposals. 
Our results echo the findings of a review of the extent to 
which 11 international organisations.3 In that review, only 
one organisation required reference to relevant system-
atic reviews in all funding applications and four funders 
required systematic reviews for funding clinical trials.3
Another important value aspect is the impact of funded 
research. Research impact broadly refers to generated 
benefits in terms of knowledge production, informing 
policy, capacity-building, health benefits and broader social 
and economic benefits.19 23 The presence of multidimen-
sional benefits reflects how the definition of impact varies 
with the perspectives of different stakeholders as patients, 
clinicians, government, industry and academia.19 23 24 The 
majority of the schemes in our review considered research 
impact as a funding criterion with elements including 
advancing knowledge, improving health outcomes and 
scientific publications; however; the schemes did not 
specify how these benefits should be measured and 
presented in funding proposals. Greenhalgh et al have 
reviewed established approaches to measure impact 
(eg, Research Impact Framework, Canadian Academy 
of Health Sciences and UK Research Excellence Frame-
work).19 They have concluded that approaches to impact 
assessment differed according to the circumstances 
and purpose of funding, they also noted that the most 
robust approaches are complex and labour-intensive and 
called for research on research impact.19 Of note, most 
of these approaches were designed to measure research 
impact retrospectively, that is, to evaluate the benefits of 
particular research programmes that have already been 
conducted; notwithstanding, funding organisations and 
researchers need prospective approaches to infer the 
benefit of new research to support research funding deci-
sions. Incorporating impact evaluation frameworks into 
the priority-setting processes is a necessary requirement 
that should be studied.7
Importantly, funding organisations may implic-
itly assume that selecting high impact projects would 
ensure value for money; nevertheless, value for money 
cannot be established without explicitly comparing the 
costs and expected benefits of proposals competing for 
funding.6 25 26 This is because research budgets are finite 
and decisions must be made about how to allocate these 
funds (ie, which research proposals should be funded) to 
maximise benefits. Failure to consider this aspect brings 
the risk of funding research projects where the costs of 
conducting research outweigh the expected research 
benefits (ie, research projects that are not cost-effec-
tive). This would result in ‘opportunity cost’, which 
is the benefit forgone elsewhere by adopting subop-
timal choices.27 Interestingly, none of the schemes that 
required demonstration of value for money provided 
guidelines on how the cost-effectiveness of research 
projects should be performed and presented. Of note, 
there are rigorous analytical methods to prospectively 
quantify the expected benefits of research on improving 
health outcomes, the key analytical approaches are the 
‘prospective payback of research’ (a similar approach 
to return on investment) and the value of information 
approach.6 8 Under the payback approach, the value of a 
research study is typically inferred from its ability to result 
in a beneficial change in clinical practice.28 The value of 
information approach, on the other hand, considers the 
uncertainty in the relevant available evidence (eg, from 
systematic reviews and meta-analyses) and the conse-
quences of this uncertainty (eg, implementing a subop-
timal intervention).25 29 Research benefits calculated by 
these approaches are scaled up by considering the popu-
lation expected to benefit from research results over time, 
and these benefits are compared with research budget to 
inform cost-effectiveness.26 30 It should be acknowledged; 
however, that assigning monetary value to research bene-
fits and conducting economic evaluation of research 
proposals may not be acceptable or feasible (eg, due to 
capacity considerations) by some jurisdictions. There-
fore, the decision making context and the availability of 
resources to conduct such analyses should be carefully 
considered before incorporating these approaches into 
priority-setting processes. Furthermore, it should be 
emphasised that the cost-effectiveness criterion should 
not be the only consideration when making research 
funding decisions. It is recommended that cost-effective-
ness be used to supplement (ie, in combination with) 
other considerations that deemed important to the stake-
holders.8 23
A limitation to our work is that we only reviewed 
active grant schemes listed on the ACGR; and therefore, 
some grant schemes may not have been included in our 
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review; however, the ACGR is a comprehensive registry 
of major research grants by leading funding organisa-
tions in Australia. Additionally, it is noted that selection 
criteria, and schemes, change over time to meet political 
and administrative objectives. For example, the NHMRC 
is revising grant schemes as well as the selection criteria 
and processes for a new series of grants to commence 
funding in 2019.31 In addition, our review was limited 
by the amount of publicly available information for each 
scheme, and thus, we could not extract some important 
elements as scheme budgets and the knowledge gener-
ation and translation frameworks adopted by various 
funding organisations. The next step for this research 
would be to engage with funding organisations to gain 
further insights on their approaches to prioritise research 
proposals for funding.
In conclusion, healthcare research is vital to improve 
health; however, there is a need to ensure that funded 
research is relevant and value for money. In selecting 
research projects for funding, Australian research 
funding organisations focus on research appropriateness, 
significance and feasibility; nevertheless, other important 
criteria should not be overlooked such as equity and stake-
holders’ engagement. Importantly, research funding deci-
sions should include an assessment of value for money in 
order to maximise return on research investment.
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